Parameter
| Biomarker | IDH1/2 Mut | Full name | IDH1/2 Mutation | Molecular Type | Gene Mutation |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, Prognosis, Risk Stratification |
| Disease | Glioblastoma | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Tumor Tissue/Plasma (NGS, Sanger Sequencing, Digital PCR) | ||
| Pathobiological Mechanisms | Mutations encoding isocitrate dehydrogenase lead to accumulation of 2-hydroxyglutarate (2-HG), inhibit histone demethylase activity, block cell differentiation, and drive tumorigenesis. | ||||
| Clinical Availability Status | Clinically available | ||||
| Notes and Dynamics | Wild-type GBM accounts for more than 90% of primary GBM with extremely poor prognosis; mutant-type is mostly secondary GBM, which can be used as a potential target for 2-HG-targeted drugs. | ||||